Acrivon Therapeutics, Inc. (ACRV): Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1…
Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Regulation FD Disclosure. Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1, Mohamad A. Salkeni2, Neel Gandhi3, Gerald Falchook4, David Sommerhalder5, Benedito A. Carneiro6, Judy Wang7, Monica Mita8,
- Product
- ACR-2316
- Milestone
- topline data
- Indication
- advanced solid tumors
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The filing provides early safety and dose-escalation context (including hematologic AEs and absence of Grade 5 events) that can affect near-term positioning in ACRV as investors assess whether the program can advance to dose expansion and later efficacy readouts.
Market read
Traders can reassess the probability of continued dose escalation and progression based on early tolerability and the absence of severe non-hematologic toxicity in the disclosed cohort.
What to watch
The data are non-QC’d with a specific cut-off, and the open-label, dose-escalation context increases the chance of later revisions or different tolerability at expansion doses.
Background
The 8-K is a Regulation FD disclosure for Acrivon’s first-in-human Phase 1/2 study of oral ACR-2316, a WEE1/PKMYT1 inhibitor designed using AP3 predictive precision proteomics.
Ticker impact
Acrivon filed an 8-K with Regulation FD disclosures describing early Phase 1/2 safety and dose-escalation results for ACR-2316 in AP3-predicted tumors.
Likely modest upside bias as traders price in progress on a first-in-class WEE1/PKMYT1 program, tempered by early Phase 1/2 uncertainty.
The disclosure includes safety (no Grade 5 AEs, no non-hematologic DLTs) and trial design details, but it is not a pivotal efficacy readout and is non-QC’d with a specific data cut-off.
Market effects
Adds incremental validation for WEE1/PKMYT1 checkpoint inhibition and AP3 proteomics-driven patient selection, which can influence sentiment across cell-cycle targeted oncology peers.
Limited direct regional impact; primarily affects US small/mid-cap biotech sentiment.
Low global spillover beyond oncology clinical-trial sentiment.
Counterpoint
Safety signals may not translate into durable efficacy; without confirmed ORR/DOR in this excerpt, the market may fade the initial enthusiasm.
Key entities
- companyAcrivon Therapeutics, Inc.
Issuer filing the 8-K and disclosing early Phase 1/2 results for ACR-2316.
- drugACR-2316
Oral, once-daily WEE1/PKMYT1 inhibitor designed to activate CDK1, CDK2, and PLK1.
- platformAP3 (Acrivon Predictive Precision Proteomics)
Proteomics-based approach used to identify AP3-predicted tumor types for enrollment.

